A multi-center, open-label clinical pharmacology study to evaluate the pharmacokinetics, pharmacodynamics and safety of TMX-049 multiple oral administration in subjects with normal renal function or impaired renal function.

Plasma exposure of TMX-049 tended to increase in patients with severe renal impairment compared to those with normal renal function, but no clear difference was observed in patients with moderate renal impairment. In both severe and moderate renal impairment groups, changes from baseline in serum uric acid levels after the TMX-049 administration were smaller than those in the normal renal function group. No specific safety concerns were identified in any of the groups.